{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '3.3', 'Exclusion Criteria', 'Subject will be excluded from participation if any of the following apply:', '1.', 'Subject has preexisting sensory or motor neuropathy Grade >', '2.', '2. Subject has active central nervous system (CNS) metastases. Subjects with treated CNS', 'metastases are permitted on study if all the following are true:', 'CNS metastases have been clinically stable for at least 6 weeks prior to screening', 'If requiring steroid treatment for CNS metastases, the subject is on a stable dose', 'VI 20 mg/day of prednisone or equivalent for at least 2 weeks', 'Baseline scans show no evidence of new or enlarged brain metastasis', 'Subject does not have leptomeningeal disease', '3. Subject has ongoing clinically significant toxicity (Grade 2 or higher with the exception', 'of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or', 'surgery). Subject with VI Grade 2 immunotherapy-related hypothyroidism or', 'panhypopituitarism may be enrolled when well-maintained/controlled on a stable dose of', 'hormone replacement therapy (if indicated). Patients with ongoing > Grade 3', 'immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects', 'with ongoing immunotherapy related colitis, uveitis, myocarditis, or pneumonitis or', 'subjects with other immunotherapy related AEs requiring high doses of steroids', '(> > 20 mg/day of prednisone or equivalent) are excluded.', '4.', 'Subject has prior treatment with EV or other MMAE-based ADCs.', '5.', 'Subject has received prior chemotherapy for urothelial cancer with all available study', 'therapies in the control arm (i.e., both prior paclitaxel and docetaxel in regions where', 'vinflunine is not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in', 'regions where vinflunine is an approved therapy).', 'Note: After vinflunine cap is reached, subjects who have received both docetaxel and', 'paclitaxel will be excluded.', '6.', 'Subject has received more than 1 prior chemotherapy regimen for locally advanced or', 'metastatic urothelial cancer, including chemotherapy for adjuvant or neo-adjuvant', 'disease if recurrence occurred within 12 months of completing therapy. The substitution', 'of carboplatin for cisplatin does not constitute a new regimen provided no new', 'chemotherapeutic agents were added to the regimen.', '7.', 'Subject has history of another malignancy within 3 years before the first dose of study', 'drug, or any evidence of residual disease from a previously diagnosed malignancy.', 'Subjects with nonmelanoma skin cancer, localized prostate cancer treated with curative', 'intent with no evidence of progression, low-risk or very low-risk (per standard', 'guidelines) localized prostate cancer under active surveillance/watchful waiting without', 'intent to treat, or carcinoma in situ of any type (if complete resection was performed) are', 'allowed.', '14 Sep 2020', 'Astellas', 'Page 51 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '8. Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or', 'fungal infection at the time of first dose of EV. Routine antimicrobial prophylaxis is', 'permitted.', '9. Subject has known active Hepatitis B (e.g., HBsAg reactive) or active hepatitis C', '(e.g., HCV RNA [qualitative] is detected).', '10. Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1', 'or 2).', '11. Subject has documented history of a cerebral vascular event (stroke or transient ischemic', 'attack), unstable angina, myocardial infarction, or cardiac symptoms (including', 'congestive heart failure) consistent with New York Heart Association Class III to IV', 'within 6 months prior to the first dose of study drug.', '12. Subject has radiotherapy or major surgery within 4 weeks prior to first dose of study', 'drug.', '13. Subject has had chemotherapy, biologics, investigational agents, and/or antitumor', 'treatment with immunotherapy that is not completed 2 weeks prior to first dose of study', 'drug.', '14. Subject has known hypersensitivity to EV or to any excipient contained in the drug', 'formulation of EV (including histidine, trehalose dihydrate, and polysorbate 20); OR', 'subject has known hypersensitivity to biopharmaceuticals produced in CHO cells.', '15. Subject has known hypersensitivity to the following:', 'docetaxel or to any of the other excipients listed in product label, including', 'polysorbate 80;', 'paclitaxel or to any of the other excipients listed in product label, including', 'macrogolglycerol ricinoleate 35 (Ph.Eur.); and', 'vinflunine or to any of the other excipient listed in product label, including other', 'vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine).', '16. [Criterion removed].', '17. Subject has known active keratitis or corneal ulcerations. Subject with superficial', 'punctate keratitis is allowed if the disorder is being adequately treated in the opinion of', 'the investigator.', '18. Subject has other underlying medical condition that, in the opinion of the investigator,', 'would impair the ability of the subject to receive or tolerate the planned treatment and', 'follow-up.', '19. History of uncontrolled diabetes mellitus within 3 months of the first dose of study drug.', 'Uncontrolled diabetes is defined as hemoglobin A1C (HbA1c) > 8% or HbAlc between', '7 and < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not', 'otherwise explained.', 'Waivers to the exclusion criteria will NOT be allowed.', '14 Sep 2020', 'Astellas', 'Page 52 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}